2023-05-03 07:05:40 ET
- Ionis Pharmaceuticals press release ( NASDAQ: IONS ): Q1 GAAP EPS of -$0.87 beats by $0.04 .
- Revenue of $131M (-7.7% Y/Y) beats by $4.12M .
- "Our first quarter results were in line with our expectations. We generated meaningful revenue while continuing to invest in key growth opportunities across our business. These results keep us on track to achieve our 2023 financial guidance," said Elizabeth L. Hougen, chief financial officer of Ionis. "We plan to continue investing in areas with the greatest potential to drive growth. As such, we expect our investments to grow modestly as we advance and expand our late-stage pipeline and move our near-term commercial opportunities toward the market. Additionally, as we keep more programs for ourselves, we expect a greater proportion of commercial revenues compared to R&D revenues, and our commercial revenues to be the primary driver of future revenue growth."
For further details see:
Ionis Pharmaceuticals GAAP EPS of -$0.87 beats by $0.04, revenue of $131M beats by $4.12M